Abstract
Despite advances in immunotherapy for other solid tumors, glioblastoma multiforme (GBM), the most common malignant primary brain tumor, has thus far demonstrated resistance to novel immunotherapeutics such as immune checkpoint inhibitors. In GBM, resistance to immunotherapy may be partly attributable to the immunosuppression that is characteristic of this disease. Both tumor-driven and iatrogenic mechanisms of immune suppression affect systemic immune status as well as the tumor microenvironment in patients with GBM. A thorough understanding of the pathophysiology of immunosuppression in GBM is needed to develop strategies to overcome resistance to immunotherapy in this disease. This chapter summarizes GBM-induced changes in circulating immune cell populations and in the tumor microenvironment and discusses how commonly used interventions in GBM patients, including radiation, chemotherapy, and corticosteroids, also result in immunosuppression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Immunotherapeutic Strategies for the Treatment of Glioma
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
